Recently Featured
Laboratory scientist working with enzyme therapy

BioMarin Licenses Investigational Fabry Disease Therapy

October 31, 2026
BioMarin Pharmaceutical has secured exclusive worldwide rights, excluding South Korea, to an investigational enzyme replacement therapy for Fabry disease from GC Biopharma and Hanmi Pharm. The agreement adds a potential treatment option for the rare genetic disorder as BioMarin expands its presence in the disease area. The licensed candidate, HM15421/GC1134A, is a long-acting recombinant alpha-galactosidase…
New bioprocessing facility in South Korea

MilliporeSigma Opens $350 Million Bioprocessing Facility in South Korea

October 31, 2026
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened a new bioprocessing production center in Daejeon, South Korea, following an investment of more than $350 million. The facility represents the company’s largest Life Science investment in the Asia-Pacific region to date and is designed to expand regional manufacturing capacity…
Meeting room with pharmaceutical professionals

PRAC Reviews Depression and Anxiety Medicine Deanxit

October 31, 2026
The Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Deanxit, a fixed-dose combination medicine used for treating depression and anxiety. This review is part of the committee’s ongoing efforts to assess the safety and efficacy of medicinal products. The agenda for the PRAC meeting held from 26 to 29 October 2026 includes discussions…
Laboratory scientist working on biopharmaceuticals

Frost & Sullivan Report Highlights China’s Growing Role in Global Biopharmaceutical Development

October 31, 2026
Frost & Sullivan has released a report analyzing the evolution of China’s biopharmaceutical industry, which is transitioning from traditional drug manufacturing to competing in international markets through innovative medicines and partnerships. The report, titled the 2026 Blue Book on the Internationalization of China’s Biopharmaceutical Industry, highlights the sector’s shift from supplying active pharmaceutical ingredients (APIs)…

Ongoing Cases